ARQT Chart
- 52-Week Range: $14.38 - $29.08
- Market Capitalization: $1.10B
- Short Percentage: 0%
- Target Price: $53.29
- Shares Outstanding: 51.42M
- Next Earnings: Nov 30
Catalysts
CategoryCatalyst
Earnings
ARQT released their earnings report for the previous quarter and provided guidance on the current and upcoming quarters.
News and Press Releases
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire | May 5th
- Arcutis: Roflumilast Has Excellent Data And High Probability Of FDA ApprovalSeeking Alpha | April 5th
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire | March 14th
- Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateGlobeNewsWire | February 22nd
- Arcutis Secures $225M Debt Financing To Fund Potential Launch Of RoflumilastBenzinga | December 23rd
- Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital PartnersGlobeNewsWire | December 23rd
- Arcutis Appoints Mas Matsuda as General Counsel and Corporate SecretaryGlobeNewsWire | December 16th
Company Info
Website: https://www.arcutis.com
Address: 3027 Townsgate Road, Westlake Village, CA, United States, 91361
Sector: Healthcare
Industry: Biotechnology
Full time employees: 147
Address: 3027 Townsgate Road, Westlake Village, CA, United States, 91361
Sector: Healthcare
Industry: Biotechnology
Full time employees: 147
$ARQT low volume today isn’t necessarily a bad thing
$ARQT Buy it up so it crashes harder in the next two trading days
$ARQT buy the dip.
$ARQT more shorts the better idc
$ARQT time will come
$ARQT good morning fellas